Trial Profile
Comparison of Short Infusion Versus Prolonged Infusion of Ceftolozane-tazobactam Among Patients With Ventilator Associated-pneumonia to Pseudomonas Aeruginosa in Intensive Care Units
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 04 Mar 2021
Price :
$35
*
At a glance
- Drugs Ceftolozane/tazobactam (Primary)
- Indications Pseudomonal infections; Ventilator associated pneumonia
- Focus Pharmacokinetics
- Acronyms CEFTOREA
- 02 Mar 2021 Planned End Date changed from 1 Jul 2021 to 1 Feb 2023.
- 02 Mar 2021 Planned primary completion date changed from 1 Jul 2021 to 1 Feb 2023.
- 29 Mar 2019 Status changed from not yet recruiting to recruiting.